India, July 8 -- Takeda India, part ofthe Takeda Pharmaceutical Company Limited, a global values-based R&D-driven biopharmaceutical leader, has announced the expansion of its highly innovative portfolio for patients in the country with the launch of Kynteles(R) (generic name: Vedolizumab) as part of its Gastrointestinal (GI) portfolio. GI is Takeda's second therapeutic area in India after Rare Diseases (Haematology, Genetic Diseases, and Immunology).

Kynteles(R) is used for the treatment of adult patients with moderate to severely active Ulcerative Colitis (UC) and Crohn's Disease (CD). Kynteles(R), more widely known as Entvyio(R), has shown favourable safety and efficacy results in treating patients suffering from moderate to severe IBD...